JOURNALOF THE BRITISHMENOPAUSE SOCIETY, July 1996 P remature ovarian failure is defined as gonadal failure before the age of 40 and it is a common condition, affecting I per cent of women I. Tragically, the diagnosis is often delayed and women affected may experience amenorrhoea for several years without receiving medical help. Sub-optimal peak bone mass may result in young women. Chromosomal analysis is needed in those under 30 years of age because of the risk of germ cell tumour.
A recent development is the possibility of pregnancy using egg donation, the success rate varying between 25 and 40 per cent depending on the age of the donor. Mary Birdsall ,provides a comprehensive account of chis procedure and the screening of recipients and donors. This important innovation offers hope to many relatively young women who wish to conceive but find they are infertile because of menopause. The ethics of ovum donation will be discussed in a later issue.
The best predictor of fracture risk is bone mineral density measurement at sites such as the femoral neck, radius and lumbar spine. This test should be available to general practitioners to
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Editorial

The impact of treatment
Dr Jean Coope Editor screen high risk patients and help with decisions on treatment, so that unnecessary medication can be avoided. Selby and Davies writing in the British Medical Journal/ describe bone-sparing treatment without measurement of bone mass as like giving antihypertensive treatment to prevent stroke in patients who present with headache but whose blood pressure has not been measured.
Unfortunately, there are still areas of Britain where there is no access to bone densitometry in the community. Juliet Compston describes the use of bone density measurements in clinical practice and pleads for a better service.
T he response of the endometrium to HRT is the subject of a review by Margaret Rees. Recent advances in treatment include a 3monthly bleeding regimen and no-bleed combined therapy after the menopause. She reaches the reassuring conclusion that these treatments are not likely to cause pre--cancerous hyperplasia.
According to Professor Beard's group at St Mary's Hospital, London, around one in five of gynaecological referrals in Britain are for chronic pelvic pain. There is now good evidence that the majority of cases (84 per cent) have pelvic venous congestion, a condition diagnosed by venography. Professor Beard's group has now developed a venography scoring system (degree of dilation, severity of congestion) with reliable and reproducible results.
Specialists and general practitioners need to meet together to discuss the best way to prescribe and supervise hormone therapy and Gillian Plant is to be congratulated on founding an HRT Club. Practice nurses, consultants, general practitioners and clinical medical officers offer their individual contributions and it is possible to provide a local consensus on managing this ever--changing field of medicine.
Oestrogen gel has been widely used on the continent of Europe for some years but data are not available concerning its possible effect in preventing osteoporotic fractures and heart disease. Bruno De Lignieres has considerable experience in using transdermal oestrogen and provides a summary of his address to the London RCOG meeting in April 1996. He states that "the large observational studies today available hardly show any vascular protection unrelated to selection bias in oral oestrogen users aged 60 or over". Most clinicians and epidemiologists would not agree with this statement as large population studies from the USA and Scandinavia demonstrate significant cardiovascular protection from oral HRT, and experiments with patients confirm the vasodilatory effect of oestrogen on blood vessels. The problem of selection bias is well recognised and is the subject of a challenging letter from messrs Ross, Stevenson and Whitehead (page 29). Bias and confounding are also addressed by the MRC's long term randomised controlled trial of hormone replacement therapy which is to commence in the near future. An account of this trial will appear in our next issue.
Finally, we would like to welcome David McKay Hart and Anthony Parsons to the Editorial Board. The Journal will be represented at the Exeter annual meeting and we would welcome suggestions as to possible future articles and content.
